艾司氯胺酮抗抑郁临床疗效的研究进展
摘要
们对于此药能够治疗不同类型的抑郁症也引发了兴趣。比如对于女性产后抑郁、成人难治性抑郁症、伴有急性自杀
意念或行为的抑郁症的治疗均有一定的治疗效果。本文就艾司氯胺酮对于各种抑郁症患者抗抑郁治疗的临床疗效是
否显著及带来的短期和长期副作用研究进展进行综述。
关键词
全文:
PDF参考
[1]抑郁症或成全球第二大疾病[J].中国报道，2017，
（11）：68.
[2]全球3亿人受抑郁症困扰[J].科学24小时，2017，
（04）：34.
[3]JAKOBSEN J C, KATAKAM K K, SCHOU A, et
al. Selective serotonin reuptake inhibitors versus placebo in
patients with major depressive disorder. A systematic review
with meta-analysis and Trial Sequential Analysis [J]. BMC
Psychiatry, 2017, 17(1): 58.
[4]章子杨，陈璟莉.艾司氯胺酮新药的临床研究进
展[J].现代临床医学，2024，50（05）：389-92.
[5]ZHANG X X, ZHANG N X, LIU D X, et al.
Research advances in the clinical application of esketamine [J].
Ibrain, 2022, 8(1): 55-67.
[6]KAUR U, PATHAK B K, SINGH A, et al.
Esketamine: a glimmer of hope in treatment-resistant
depression [J]. Eur Arch Psychiatry Clin Neurosci, 2021,
271(3): 417-29.
[7]KAMP J, JONKMAN K, VAN VELZEN M, et
41
医学理论研究 | 第3卷/第3期
Medical Theory Research
al. Pharmacokinetics of ketamine and its major metabolites
norketamine, hydroxynorketamine, and dehydronorketamine: a
model-based analysis [J]. Br J Anaesth, 2020, 125(5): 750-61.
[8]XU M, WANG J, SHI J, et al. Esketamine mitigates
endotoxin-induced hippocampal injury by regulating calcium
transient and synaptic plasticity via the NF-α1/CREB
pathway [J]. Neuropharmacology, 2025, 269: 110362.
[9]PARSAEI M, HASEHMI S M, SEYEDMIRZAEI H,
et al. Perioperative esketamine administration for prevention
of postpartum depression after the cesarean section: A
systematic review and meta-analysis [J]. J Affect Disord, 2024,
361: 564-80.
[10]REN L, ZHANG T, ZOU B, et al. Intraoperative
Esketamine and Postpartum Depression Among Women With
Cesarean Delivery: A Randomized Clinical Trial [J]. JAMA
Netw Open, 2025, 8(2): e2459331.
[11]DI NICOLA M, PEPE M, D'ANDREA G, et al.
Patient Experience with Intranasal Esketamine in TreatmentResistant Depression: Insights from a Multicentric Italian
Study (REAL-ESKperience) [J]. J Pers Med, 2025, 15(4).
[12]POPOVA V, DALY E J, TRIVEDI M, et al.
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray
Combined With a Newly Initiated Oral Antidepressant in
Treatment-Resistant Depression: A Randomized DoubleBlind Active-Controlled Study [J]. Am J Psychiatry, 2019,
176(6): 428-38.
[13]MCINTYRE R S , ROSENBLAT J D ,
NEMEROFF C B, et al. Synthesizing the Evidence for
Ketamine and Esketamine in Treatment-Resistant Depression:
An International Expert Opinion on the Available Evidence and
Implementation [J]. Am J Psychiatry, 2021, 178(5): 383-99.
[14]ZAKI N, CHEN L N, LANE R, et al. Safety and
efficacy with esketamine in treatment-resistant depression:
long-term extension study [J]. Int J Neuropsychopharmacol,
2025, 28(6).
[15]DALY E J, TRIVEDI M H, JANIK A, et al.
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant
Treatment for Relapse Prevention in Patients With
Treatment-Resistant Depression: A Randomized Clinical
Trial [J]. JAMA Psychiatry, 2019, 76(9): 893-903.
[16]KATZ E G, HOUGH D, DOHERTY T, et
al. Benefit-Risk Assessment of Esketamine Nasal Spray
vs. Placebo in Treatment-Resistant Depression [J]. Clin
Pharmacol Ther, 2021, 109(2): 536-46.
[17]CEBAN F, ROSENBLAT J D, KRATIUK K, et
al. Prevention and Management of Common Adverse Effects
of Ketamine and Esketamine in Patients with Mood Disorders
[J]. CNS Drugs, 2021, 35(9): 925-34.
[18]BAUDOT J, SOEIRO T, TAMBON M, et
al. Safety concerns on the abuse potential of esketamine:
Multidimensional analysis of a new anti-depressive drug on
the market [J]. Fundam Clin Pharmacol, 2022, 36(3): 572-81.
[19]NIKAYIN S, MURPHY E, KRYSTAL J H, et al.
Long-term safety of ketamine and esketamine in treatment of
depression [J]. Expert Opin Drug Saf, 2022, 21(6): 777-87.
[20]CHIAPPINI S, GUIRGUIS A, SCHIFANO N, et
al. Comparative safety of prescribed Esketamine and ketamine
in relation to renal and urinary disorders: A pharmacovigilance
perspective [J]. Prog Neuropsychopharmacol Biol Psychiatry,
2025, 136: 111213.
[21]AMMENDOLIA I, MANNUCCI C, ESPOSITO
E, et al. Safety Profile and Suicidality Associated with the Use
of Esketamine in the Treatment of Major Depressive Disorder
in European Countries: An EudraVigilance Database Analysis
[J]. Pharmaceuticals (Basel), 2025, 18(5).
[22]FEDGCHIN M, TRIVEDI M, DALY E J, et al.
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray
Combined With a New Oral Antidepressant in TreatmentResistant Depression: Results of a Randomized, DoubleBlind, Active-Controlled Study (TRANSFORM-1) [J]. Int
J Neuropsychopharmacol, 2019, 22(10): 616-30.
[23]DI VINCENZO M, MARTIADIS V, DELLA
ROCCA B, et al. Facts and myths about use of esketamine
for treatment-resistant depression: a narrative clinical review
[J]. Front Psychiatry, 2024, 15: 1394787.
[24]王群，季加富，迟永良，et al.艾司氯胺酮在围
手术期的应用进展[J].中国新药与临床杂志，2024，43
（01）：12-6.
[25]SKALA K, DOGANAY K, EDER H, et al.
Intranasal esketamine as therapeutic option: a case report of
an adolescent with treatment resistant depression [J]. Front
Psychiatry, 2023, 14: 1118737.
[26]武琼，崔栋然，王瑞，et al.不同剂量艾司氯胺
酮用于老年全身麻醉手术患者麻醉诱导对血流动力学、
应激反应、术后谵妄影响[J].临床军医杂志，2024，52
（01）：95-8.
Refbacks
- 当前没有refback。
